Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hidalgo

Showing results (431-440 of 456) with videos related to

Pageof 46
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2012
Retrospective study assessing the role of MRI in the diagnostic procedures for early breast carcinoma: a correlation of new foci in the MRI with tumor pathological featuresI Calvo-Plaza, L Ugidos, C Miró, et al.
Revista Espanola De Las Enfermedades Del Aparato Digestivo|July 1, 1982
[Distal splenorenal shunt. 8 years' experience]E Moreno González, G García Blanch, A de la Calle Santiuste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxelM Hidalgo, C Aylesworth, L A Hammond, et al.
British Journal of Cancer|July 29, 2010
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancerI Garrido-Laguna, A C Tan, M Uson, et al.
Archivos De Cardiologia De Mexico|March 25, 2014
[Influence of age in short and long term prognostic of ischemic cardiogenic shock]Víctor M Hidalgo-Olivares, Juan Gabriel Córdoba-Soriano, Isabel López-Neira, et al.
British Journal of Cancer|March 20, 2014
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'R Alvarez, M Musteanu, E Garcia-Garcia, et al.
JAMA Network Open|October 27, 2025
Modified Clavien-Dindo Classification for Adverse Events in Otolaryngology-Head and Neck SurgeryCecelia M Hidalgo, Eliot J Martin, Daniel G Eyassu, et al.
British Journal of Cancer|August 3, 2013
Stromal disrupting effects of nab-paclitaxel in pancreatic cancerR Alvarez, M Musteanu, E Garcia-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignanciesM Hidalgo, M A Villalona-Calero, S G Eckhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2013
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancerB M Wolpin, E M O'Reilly, Y J Ko, et al.
Pageof 46

Showing results (431-440 of 456) with videos related to

Sort By:
Pageof 46
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 9, 2012
Retrospective study assessing the role of MRI in the diagnostic procedures for early breast carcinoma: a correlation of new foci in the MRI with tumor pathological featuresI Calvo-Plaza, L Ugidos, C Miró, et al.
Revista Espanola De Las Enfermedades Del Aparato Digestivo|July 1, 1982
[Distal splenorenal shunt. 8 years' experience]E Moreno González, G García Blanch, A de la Calle Santiuste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2001
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxelM Hidalgo, C Aylesworth, L A Hammond, et al.
British Journal of Cancer|July 29, 2010
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancerI Garrido-Laguna, A C Tan, M Uson, et al.
Archivos De Cardiologia De Mexico|March 25, 2014
[Influence of age in short and long term prognostic of ischemic cardiogenic shock]Víctor M Hidalgo-Olivares, Juan Gabriel Córdoba-Soriano, Isabel López-Neira, et al.
British Journal of Cancer|March 20, 2014
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'R Alvarez, M Musteanu, E Garcia-Garcia, et al.
JAMA Network Open|October 27, 2025
Modified Clavien-Dindo Classification for Adverse Events in Otolaryngology-Head and Neck SurgeryCecelia M Hidalgo, Eliot J Martin, Daniel G Eyassu, et al.
British Journal of Cancer|August 3, 2013
Stromal disrupting effects of nab-paclitaxel in pancreatic cancerR Alvarez, M Musteanu, E Garcia-Garcia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignanciesM Hidalgo, M A Villalona-Calero, S G Eckhardt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 2, 2013
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancerB M Wolpin, E M O'Reilly, Y J Ko, et al.
Pageof 46